Okeiro

The Paris-based firm develops an AI-powered clinical decision support platform designed to prevent organ failure in transplant patients and individuals with advanced chronic diseases affecting the kidneys, lungs, heart, and liver. Its core technology, the iBox algorithm, is a predictive model marked as a medical device and qualified by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) as a surrogate endpoint. This algorithm integrates multiple data points, including biological, immunological, and clinical parameters, to accurately predict graft survival at three, five, and seven years post-transplant.

Okeiro operates on a multi-faceted business model, serving two primary client types. For healthcare professionals and hospitals, the company provides a platform that offers a clear overview of patient data, enabling early detection of complications and proactive treatment adjustments. The technology is already implemented in French hospitals and has achieved national reimbursement status from the French National Health Insurance. For pharmaceutical companies, the iBox algorithm accelerates clinical trials by providing early, reliable predictions of long-term graft survival, which can facilitate earlier market access for new drugs. The company is conducting randomized clinical trials across 16 hospitals in six countries to further demonstrate its technology's effectiveness.